Innate Pharma : H1 2022 update: the key takeaways are the AZN agreement and lacutamab
>€ 158m in cash at end-June 2022 - Innate Pharma this morning released its results for H1 2022. The operating result was in positive territory at € 8.5m (vs -€ 19.2m in 2021) under the impact of the increase in operating revenues (€ 45.6m vs € 14.6m one year previously) stemming mainly from the payments received as part of the collaboration agreements forged with AstraZeneca and Sanofi.The cash position at end-June 2022 stood at € 158.2m (vs € 159.7m at end-2021)...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.